Last Updated: September 24, 2026

Litigation Details for Smart Denture Conversions, LLC v. Straumann USA, LLC (D. Del. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Smart Denture Conversions, LLC v. Straumann USA, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Smart Denture Conversions, LLC v. Straumann USA, LLC (D. Del. 2024)

Last updated: July 13, 2026

Smart Denture Conversions, LLC v. Straumann USA, LLC (1:24-cv-00507): Litigation Summary, Claims at Issue, and Infringement Exposure

Smart Denture Conversions, LLC sued Straumann USA, LLC in the U.S. District Court in a new patent infringement action filed under docket number 1:24-cv-00507. The case centers on “Smart Denture” conversion workflows and related dental-manufacturing IP, with Straumann USA accused of infringing one or more asserted patents tied to denture conversion and/or dental implant prosthetics tooling and methods. No substantive merits outcome is reflected in the docket to date.

What is Smart Denture Conversions, LLC v. Straumann USA, LLC (1:24-cv-00507) about?

Featured snippet answer: The case is a newly filed patent infringement action in which Smart Denture Conversions, LLC accuses Straumann USA, LLC of infringing patents related to denture conversion processes and associated dental product workflows.

Who are the parties and what are the roles in the dispute?

  • Plaintiff: Smart Denture Conversions, LLC
  • Defendant: Straumann USA, LLC
  • Court: U.S. District Court (case caption reflects federal jurisdiction)
  • Docket: 1:24-cv-00507
  • Nature: Patent infringement (types of pleadings typical for conversion and prosthetic workflow IP cases include infringement allegations, claim construction positions, and infringement contentions)

What patents are asserted and what claim themes typically drive these Smart Denture conversion suits?

The core claim themes in “smart denture conversion” litigation tend to cluster around:

  • Methods for converting a dental prosthesis workflow (conversion steps, digital-to-physical manufacturing steps, or conversion protocols)
  • Systems or kits used to perform conversion (conversion components, fixtures, digital tooling, or conversion instructions)
  • Dental prosthetic alignment, fitting, and manufacturing methods that map to implant-supported configurations

The docket and publicly indexed materials must be read to confirm the exact asserted patent numbers, independent claims, and whether infringement theories are system-, method-, or kit-based. No claim-by-claim specifics can be stated here without the complaint or infringement contentions.

When was the case filed, and what are the key procedural milestones?

Featured snippet answer: The action is in early procedural posture as of its 2024 filing, with no final merits decision reflected in publicly indexed docket data.

Filing and docket chronology (what to track)

In early-stage patent cases, the key milestones that affect infringement exposure and leverage typically include:

  • Complaint filing and service date
  • Defendant’s motion to dismiss (if any)
  • Early claim construction scheduling order
  • Patent owner’s service of infringement contentions
  • Defendant’s service of invalidity contentions
  • Markman hearing date (if scheduled)
  • Initial case management conference
  • Any settlement or consent orders that affect trial schedule

For 1:24-cv-00507, the relevant dates and orders must be pulled from the docket sheet to populate a reliable timeline.

What patents protect Smart Denture conversions and denture conversion workflows?

Featured snippet answer: Smart Denture conversion litigation typically targets patent claims covering denture-to-implant conversion methods, conversion systems, and manufacturing protocols for prosthetic fitting. The exact patent estate in this case must be validated against the asserted patent list in the complaint.

Typical patent categories in denture conversion IP

These suits usually assert one or more of:

  • Method patents: stepwise conversion processes, including digital design, fixture selection, or conversion milling/printing steps
  • System patents: devices, fixtures, and components enabling conversion
  • Computer-implemented process patents: workflow logic, conversion mapping, or data transformation steps used in the conversion process
  • Kit patents: packaging of components used in the conversion workflow

How strong are the asserted patents in conversion and prosthetic IP?

Strength depends on:

  • Claim scope (broad method steps vs narrow device-specific limitations)
  • Prior art density in CAD/CAM dental workflows
  • Whether independent claims require specific hardware, specific digital inputs, or specific conversion steps
  • Whether asserted patents have prosecution history narrowing that limits enforceable scope

Without the asserted patent numbers and claim excerpts, patent strength cannot be scored for this specific case.

What does Straumann USA, LLC allegedly infringe?

Featured snippet answer: The complaint alleges Straumann’s products and/or conversion-related offerings practice one or more asserted conversion-related method and/or system claims. The infringement theory is typically product use plus inducement or direct infringement by customers performing the conversion workflow.

Direct infringement vs indirect theories

Patent plaintiffs in this space often plead:

  • Direct infringement: Straumann products used in a conversion workflow that meets claim limitations
  • Induced infringement: Straumann provides instructions, marketing, training, or documentation that leads customers to perform the claimed method
  • Contributory infringement (less common in very process-heavy workflows): components specifically made for conversion and not suitable for substantial non-infringing use

The exact pleading structure in 1:24-cv-00507 must be confirmed from the complaint and any infringement contentions.

What claim construction issues matter most in denture conversion litigation?

Featured snippet answer: Claim construction usually turns on whether “conversion steps” and “system” limitations are narrowly tied to specific hardware and data inputs or are broad enough to cover multiple implementation variants.

Key construction levers to expect

In CAD/CAM and prosthetic conversion cases, courts commonly resolve:

  • Whether functional language requires particular structural embodiments
  • Whether “conversion” means a specific transformation of a denture state or a generic workflow
  • Whether “digital model,” “scan data,” or “patient-specific” limitations require particular formats or only any digital representation
  • Whether a “system” must include all components together or covers distributed tooling across a workflow

Populate this section only with the actual asserted claim language and the parties’ construction positions from the docket.

What motions have been filed, and how have they affected the case?

Featured snippet answer: No merits disposition is reflected in the publicly indexed record; motion practice may exist but is not enumerated here without the docket extract.

Motion categories that most often appear

In patent cases of this type, typical motions include:

  • Motion to dismiss under Rule 12(b)(6) for failure to state a plausible infringement theory
  • Motions related to venue and personal jurisdiction
  • Motions to stay pending PTAB proceedings (inter partes review, post-grant review, or covered business method challenges)
  • Motion to compel discovery or enforce infringement contentions
  • Claim construction-related submissions ahead of a Markman

Has Straumann challenged validity (PTAB or invalidity contentions)?

Featured snippet answer: Validity challenges typically come from defendant invalidity contentions and may include PTAB petitions; the specific posture for 1:24-cv-00507 requires a docket-and-patent-by-patent review.

PTAB risk signals in dental workflow patents

Common PTAB invalidity theories include:

  • Anticipation by prior dental CAD/CAM workflows or known prosthetic conversion methods
  • Obviousness combining a workflow disclosure with known prosthetic components or digital fitting methods
  • Rejection of computer-implemented limitations for lack of novel technical features (depends on patent drafting and claim construction)

Without the asserted patents’ numbers, no PTAB attack can be reliably mapped.

What is the Orange Book status, and are there any FDA pathway implications?

Featured snippet answer: Orange Book listing applies to approved small-molecule and certain biologics drug products; this case is a device/workflow patent dispute tied to dental prosthetics conversion, so Orange Book status is not the relevant exclusivity framework. FDA exclusivity or Orange Book listing does not typically govern patent infringement for conversion hardware and methods.

No credible Orange Book mapping can be produced without knowing whether the asserted patents relate to an FDA-approved drug product, which is not indicated by the case name alone.

What is the commercial exposure for Straumann USA if infringement is proven?

Featured snippet answer: Exposure can include reasonable royalty damages, potentially enhanced damages if willfulness is pleaded and supported, and injunctive relief depending on the adequacy of legal remedies and whether the asserted patents are device- or method-limited.

Damage components typically at issue in dental prosthetic patent cases

  • Lost profits: if plaintiff proves demand and customer lock-in tied to the accused offerings
  • Reasonable royalty: often the fallback measure based on comparable licenses or Georgia-Pacific factors
  • Willfulness and enhanced damages: driven by pre-suit notice, internal evaluation, and litigation conduct
  • Attorneys’ fees: tied to exceptional case standards

How to bound royalty exposure using plausible commercial drivers

For conversion workflows involving established dental device ecosystems:

  • Market share in implant prosthetics or conversion-related offerings
  • Attach rate of conversion products or kits
  • Revenue per conversion case and margin
  • Contract structure with dental labs and clinics

A quantified exposure range requires product mapping and the asserted claim coverage, which cannot be done here without complaint specifics and accused product identification from docket materials.

How could this case play out procedurally and strategically?

Featured snippet answer: Early-stage patent cases in this category typically resolve through claim construction, early settlement after damages theories clarify, or through PTAB-driven narrowing that changes infringement or invalidity outcomes.

Likely inflection points

  • Markman ruling: can narrow claims to specific hardware/software or broaden them across multiple Straumann implementations
  • Infringement contentions refinement: often narrows accused products to fewer configurations
  • PTAB decisions: may reduce remaining asserted claims, especially when independent claim breadth is attacked
  • Summary judgment: can eliminate non-infringing embodiments if claim scope is narrow

What similar litigation affects Smart Denture conversions or Straumann’s prosthetics portfolio?

Featured snippet answer: No reliable list of related cases can be produced for 1:24-cv-00507 without performing a docket-by-docket and patent-by-patent landscape query against the asserted patent numbers.

What to search for in a landscape review (once asserted patents are known)

  • Other defendants accused of infringing the same conversion patents
  • Co-pending Smart Denture cases, if any, involving CAD/CAM workflow or prosthetics conversion
  • Straumann’s prior freedom-to-operate or IP disputes around conversion workflows
  • License agreements involving the same conversion patent families

Key Takeaways

  • Smart Denture Conversions, LLC v. Straumann USA, LLC (1:24-cv-00507) is a newly filed federal patent infringement dispute centered on denture conversion-related IP.
  • The case is in early procedural posture; there is no final merits outcome reflected in the available docket-level summary.
  • The litigation’s impact and commercial exposure depend on the asserted patent list, claim language, and how the accused Straumann offerings are mapped to those limitations.
  • The strategic drivers likely include Markman claim construction, infringement contentions narrowing, and potential PTAB challenges (if asserted patents face invalidity attacks).

FAQs

1) What is the current status of docket 1:24-cv-00507?
The case is pending with no final merits disposition reflected in the high-level docket summary available here.

2) Which patents does Smart Denture Conversions assert against Straumann in this case?
The specific asserted patent numbers must be taken from the complaint; they are not enumerated in the information available in this request.

3) Can Straumann avoid liability by changing its conversion workflow?
If the asserted claims are method- or system-limited, Straumann can reduce infringement risk by avoiding claim-required steps and configurations, but the feasibility depends on the construed claim scope.

4) Do PTAB proceedings typically run in parallel with infringement cases like this one?
Yes, defendants often file IPR/PGR petitions to narrow or invalidate asserted claims while the infringement action proceeds, but the specific posture for this docket must be sourced from the case record.

5) What remedies could Smart Denture Conversions seek if it wins?
Typical remedies include reasonable royalty damages, possible enhanced damages for willfulness if supported, attorneys’ fees in exceptional cases, and potential injunctive relief depending on the asserted claims’ nature.


References (APA)

  1. U.S. District Court docket for Smart Denture Conversions, LLC v. Straumann USA, LLC, Case No. 1:24-cv-00507.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.